# Psilocybin for Treatment-Resistant Depression in Autism

> **NCT06731621** · PHASE1 · RECRUITING · sponsor: **Centre for Addiction and Mental Health** · enrollment: 20 (estimated)

## Conditions studied

- Treatment Resistant Depression
- Autism Spectrum Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT06731621
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731621, "Psilocybin for Treatment-Resistant Depression in Autism". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06731621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*